Kyowa Kirin and Grünenthal collaborate on therapy portfolio
The deal covers 13 brands across six therapeutic areas, mainly focused on pain treatment
Read More
Tag: Grünenthal
King’s College London and Grünenthal join forces to ease pain
Duo will collaborate to develop pluripotent stem cell-based microfluidic cultures for pain research
Read More
AZ sells rights to statin med Crestor to Grünenthal
Grünenthal will pay $320m upfront for the rights
Read More
AZ divests migraine drug to Grünenthal
AstraZeneca has sold global rights (ex Japan) for its migraine drug Zomig to Grünenthal, as it continues to shed products outside of its area of strategic focus.
Read More
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
